[A18-05] Sofosbuvir/velpatasvir/voxilaprevir (chronic hepatitis C) - Addendum to Commission A17-35
Last updated 15.02.2018
Project no.:
A18-05
Commission:
Commission awarded on 09.01.2018 by the Federal Joint Committee (G-BA).
Report type:
Addendum
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Immune system and infections
Indication:
Chronic hepatitis C
Result of dossier assessment:
DAA-naive adults with CHC genotype 3 without cirrhosis: hint of non-quantifiable, at most minor added benefit. Remaining 12 research questions: unchanged
Note:
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.
| Project no. | Title | Status |
|---|---|---|
| A17-35 | Sofosbuvir/velpatasvir/voxilaprevir (chronic hepatitis C) – Benefit assessment according to §35a Social Code Book V | Commission completed |
Federal Joint Committee (G-BA)
2018-02-15 A G-BA decision was published.